Dynamic changes of throat swabs RNA and serum antibodies for SARS-CoV-2 and their diagnostic performances in patients with COVID-19

Xueping Qiu,*, Yang Xiang,*, Jianbin Sun,*, Xinrui Wang, Guoqiang Chen, Xianqun Xu, Shengjun Liao, Na Yang, Siwei Li, Gang Yang, Yueting Tang, Junli Fan, Wen Xie, Hanning Hu, Yirong Li and Fang Zheng

Abstract

Dynamic changes of RNA and antibodies in SARS-CoV-2 infected patients remain largely unknown, and influence factors for antibody production have not been fully clarified. In this study, consecutive throat swabs specimens (n = 1875) from 187 patients were collected to analyse the dynamic changes of RNA. Moreover, 162 serial serum samples from 31 patients were tested for seroconversion of IgM and IgG. Meanwhile, IgM and IgG were also detected in 409 COVID-19 patients and 389 controls. Additionally, the logistic regression analysis was executed to identify the possible influence factors for antibody production. The median positive conversion time for RNA was day 7 (IQR, 3–11), and the positive rate was highest in day 1–5 (74.59 %) and then gradually decreased. The median time of seroconversion for IgM and IgG were both day 12 (IQR, 10–15). The sensitivity and specificity for IgM (or IgG) was 87.04% and 96.92%, respectively. Multivariate logistic regression indicated that reduced lymphocytes and short positive conversion time for SARS-CoV-2 RNA were independent factors for negative results of IgM and IgG. In conclusion, RNA and antibodies should be combined for COVID-19 diagnosis, and delayed seroconversion was influenced by the decreased lymphocytes and short positive conversion time for RNA.

Introduction

Since novel coronavirus pneumonia (COVID-19) outbreak in December 2019, the number of reported cases has surpassed 3,672,238 with over 254,045 deaths worldwide, as of May 8, 2020 [1]. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of coronaviruses is known to cause COVID-19 with common colds and severe illnesses such as Acute Respiratory Distress Syndrome (ARDS) [2].

A prompt and accurate diagnosis on the infection of SARS-CoV-2 is the cornerstone of the endeavours to offer appropriate management for patients and prevent further spread of the virus. So far, real-time quantitative PCR (RT-qPCR) depends on many factors, including sample types, different disease stages and skills for sample collection [7]. Though pharyngeal virus shedding was very high and infectious virus was readily isolated during the first week after onset of symptom, the RNA testing results turned to be negative from day-14 [8]. Compared with RT-qPCR, antibodies determination is advantageous with biosecurity, short turn-around time and high repeatability due to the homogeneity of blood samples [9]. However, antibodies titres are largely depended on the time course of antibody responses after infection, and they could be negative in the window periods [9]. So, we executed the present study to profile the positive conversion of RNA and antibodies, evaluate the diagnostic performances of RNA testing and antibody determination, and recommend a laboratory diagnostic flow in different stages of COVID-19.
Materials and methods

Sample collection

A total of 475 RT-qPCR confirmed cases of COVID-19 individuals and 389 cases of controls (non-COVID-19 patients) were enrolled from four medical institutions in Hubei Province between January 20, 2020 and March 12, 2020. These medical institutions included Zhongnan Hospital of Wuhan University, Wuhan Third Hospital-Tongren Hospital of Wuhan University, Huang Gang Central Hospital and Hebi City Center for Disease Control and Prevention. All cases were adult (age ≥ 18) and the pregnant women were excluded in this study. The diagnosis and clinical classification criteria of COVID-19 was based on the Guidelines for Diagnosis and Treatment of Novel Coronavirus Pneumonia (7th version) [3], released by National Health Commission of the People’s Republic of China. The clinical data was obtained from the electronic medical records of patients. The data included demographic information, major comorbidities, the date of symptom onset, clinical classification, SARS-CoV-2 RNA testing results and other clinical laboratory test results. Written informed consent was waived and the study was approved by the Medical Ethical Committee of Zhongnan Hospital of Wuhan University, Wuhan Third Hospital-Tongren Hospital of Wuhan University, Huang Gang Central Hospital and Hebi City Center for Disease Control and Prevention.

SARS-CoV-2 RNAs detection

Throat swabs were collected from patients and soaked into the virus preservation solution immediately (Zhongzhi, Wuhan, China). The total RNAs was extracted using the respiratory sample RNA isolation kit (Zhongzhi, Wuhan, China) according to the manufacturer’s recommendation, and then amplified using reverse transcription real-time quantitative PCR assays (RT-qPCR), following the recommended standard operating protocols provided by the SARS-CoV-2 Nucleic Acid Diagnostic Kit (Sun Yat sen University Daan gene Co., Ltd, Guanzhou, China). The reaction mixture was used for both RNA reverse transcription and target genes amplification. The target genes include the open reading frame 1ab (ORF1ab) gene, and the nucleocapsid protein (N) gene of SARS-CoV-2. The results of the RT-qPCR were analysed according to the manufacturer’s protocol.

Antibody testing

The IgM and IgG antibody against SARS-CoV-2 in serum samples were tested using chemiluminescent microparticle immunoassay (CLIA Microparticles) kits supplied by Autobio Diagnostics Co., Ltd (Henan, China), according to the manufacturer’s instructions. Briefly, the IgM μ-chain capture method was used to detect the IgM antibodies, based on the HRP-conjugated recombinant spike protein of SARS-CoV-2. In the first step, the IgM antibodies in samples bind to the mouse anti-human IgM coated on the microparticles. In the second step, after washing, the HPR-conjugated SARS-CoV-2 antigen in the Enzyme Conjugate was allowed to react with the SARS-CoV-2 IgM already bound to the solid phase in the first step. A complex of antibodies in the sample combined with enzyme-linked antigens was generated among the solid phase, by immunological reactions. However, the IgG antibodies were tested using an indirect method based on a recombinant spike antigen and HRP-conjugated anti-human IgG. In the first step, SARS-CoV-2 IgG antibodies in samples bind to recombinant SARS-CoV-2 antigen coated microparticles. In the second step, after washing, a complex of the SARS-CoV-2 IgG in samples binding with HRP-conjugated anti-human IgG were generated by immunological reactions, was fixed on the solid phase. In the following steps of IgM or IgG detection methods, chemiluminescent substrate was added, and then the complex catalyses substrate, resulting in a chemiluminescent reaction. The resulting chemiluminescent reaction was measured as RLU (relative light units). The RLU was proportional to the amount of SARS-CoV-2 IgM/IgG in the samples.

The antibody levels were expressed using the relative binding signals compared to the cutoff value of each assay (S/CO). Samples with S/CO ≥ 1 were considered positive.

Statistical analysis

Continuous variables were properly presented as mean ± SD or as median (IQR: interquartile range, IQR). Categorical variables were presented as frequencies (n) and percentages (%). Comparisons between continuous variables in different groups were performed by student’s t test or Mann–Whitney U test where necessary. Chi-squared test was used to compare categorical variables between groups, while the Fisher exact test was used when the data were limited. Univariate and multivariate binary logistic regression analysis were used to identify the influence factors for antibody testing results. The statistical analyses were conducted with the SPSS 20.0, all p-values were two-sided and p < 0.05 was considered statistically significant.

Results

SARS-CoV-2 RNA detection by RT-qPCR in consecutive throat swabs specimens for COVID-19 patients

A total of 1875 throat swab specimens were collected from 187 COVID-19 confirmed patients who detected
SARS-CoV-2 RNA for equal to or more than 5 times. Each patient test SARS-CoV-2 RNA for 10 times on average and the total positive rate was 40.65% (763/1877) (Supplementary Table S1). The results of sequential SARS-CoV-2 RNA detection results for each patient within day 60 were shown in Supplementary Figure S1. The median positive conversion time for SARS-CoV-2 RNA (defined as the first positive time point of RNA tests) was day 7 (IQR, 3–11). There were 160 patients (85.56%, 160/187) received positive results at the first time of RNA test, and the other 27 patients (14.44%, 27/187) underwent multiple RNA tests until positive results were obtained.

Considering the disease stage may affect the detection of viral RNA, we analysed the positive rate of throat swabs for SARS-CoV-2 RNA in different stages (Figure 1 and Supplementary Table S1). It was clearly observed that the positive rate of RNA was the highest in the early stage (day 1–5) and gradually decreased as the disease duration was prolonged. The RNA positive rate decreased from 74.59% in the early stage (day 1–5) to 15.67% in the advanced stage (day > 50 since onset).

**Positive conversion of antibodies and RNA against SARS-CoV-2 in patients with COVID-19**

A total of 162 serial serum samples were collected from 31 COVID-19 patients during the hospitalization period. All the serum specimens of these patients were collected and tested for equal to or more than three times. And each patient tested for antibodies against SARS-CoV-2 for 5.23 times on average. The median time of seroconversion for IgM and IgG were both the day 12 (IQR, 10–15). The cumulative seropositive rate reached 54.84% and 51.61% on the 12th day for IgM and IgG, respectively (Figure 2). Moreover, the cumulative seropositive rate reached 100% on the 36th-day for both IgM and IgG (Figure 2). The seroconversion was closely and sequentially appeared for IgM and then IgG.

In order to know the changes for antibody and RNA against the SARS-CoV-2 in the same patient, we further analysed the RNA result of these 31 patients before day 51. The cumulative RNA positive rate was 64.52% before the 7th day, and it reached 100% on the 14th-day (Figure 2). The longitudinal changes of antibody and RNA in 10 representative patients were presented in Figure 3, and the others were displayed in Supplementary Figure S2. The first positive time point of RNA tests appeared earlier than that of IgM in 28 of 31 patients (28/31, 90.32%), except for patient No.1, No.20 and No.31 (at the same day). When it comes to IgG, the seroconversion time of 29 cases (29/31, 93.55%) were later than the positive conversion time of RNA, and the rest (2/31, 6.45%, patient No.1 and No.20) were the same as RNA. It should be noted that the risings of antibodies were not always
accompanied by RNA clearance, especially the patient No. 31 (Figure 3(J)).

**The sensitivity and specificity for serological methods**

We enrolled 409 cases (217 males vs. 192 females) with COVID-19 and 389 controls (224 males vs. 165 females) so as to explore the sensitivity and specificity for serological methods. And the median age was 60 years (IQR, 49-69) and 45 years (IQR, 29-61) for patient with and without COVID-19, respectively (Table 1).

The IgM and IgG antibodies were detected positive as early as on the day-3 since onset of the symptom. The sensitivity and specificity for IgM to distinguish...
The COVID-19 patients and non-COVID-19 patients was 87.04% (95% CI, 83.77–90.31%) and 96.92% (95% CI, 95.19–98.64%), respectively. As for IgG, it had the same sensitivity and specificity as IgM. Furthermore, the serological methods showed a high consistent with the results of SARS-CoV-2 RT-qPCR testing (kappa = 0.84, p < 0.0001, both IgM and IgG). Noteworthy, combining the results of IgM and IgG (patients with either IgM or IgG positive) would increase the sensitivity to 88.75% (95% CI, 85.68–91.83%), and the consistency with RNA to 0.85 (kappa = 0.85, p < 0.0001). Moreover, 15 controls (negative SARS-CoV-2 RT-qPCR testing) had positive results for IgM or IgG, all these cases with respiratory symptoms, which indicated that these cases may be missed by SARS-CoV-2 RT-qPCR testing or false positive results. However, there were 53 samples showed seronegative for both IgM and IgG, possibly due to that most samples (39/53, 73.58% for IgM; 45/53, 84.91% for IgG) involved were collected at the early stage of illness (IgM: 39 earlier than day-12, 5 on day-13 to day-15, the other 9 were later than day-20; IgG: 45 earlier than day-12, 6 on day-13 to day-15, the other 2 were later than day-20).

The logistic regression analysis identified influence factors for seroconversion in patients with COVID-19

There were 163 confirmed COVID-19 patients with complete clinical data were selected to compare the differences in the baseline demographic, clinical and biochemical characteristics of IgM (or IgG) positive and negative patients (Table 2). Of these patients, 130 (79.75%) and 127 (77.91%) patients tested positive for IgM and IgG antibodies, respectively. Female patients with COVID-19 were more prone to have negative results for IgG (p = 0.0148). Compared with the antibody positive patients, patients with negative antibody tests had lower lymphocyte counts (p = 0.0005 for IgM, p = 0.0046 for IgG) and a higher proportion of critical degree patients (p = 0.0014 for IgM, p = 0.0190 for IgG), while as disease severity increasing the lymphocyte counts was gradually decreased (Figure 4). Besides, individuals with short SARS-CoV-2 RNA positive conversion time were more likely to have negative antibodies test results (p = 0.0228 for IgM, p = 0.0022 for IgG). Noteworthy, the comorbidities, such as hypertension (p = 0.0239) and cardiovascular-cerebrovascular diseases (p = 0.0190) might also correlate with negative results in IgM test.

Univariate and multivariate binary logistic analysis were used to analyse the influencing factors of antibody testing (Table 3). Univariate logistic analysis revealed that lymphocyte counts (p = 0.001 for IgM, p = 0.006 for IgG) and SARS-CoV-2 RNA positive conversion time (p = 0.014 for IgM, p = 0.003 for IgG) were
| Variables                        | IgM Positive (n = 163) | IgM Negative (n = 33) | p       | IgG Positive (n = 163) | IgG Negative (n = 36) | p       |
|----------------------------------|------------------------|----------------------|---------|------------------------|----------------------|---------|
| No.                              | 130                    | 33                   |         | 127                    | 36                   |         |
| Age, year                        | 53.86 ± 14.98          | 57.52 ± 15.31        | 0.2147a | 54.02 ± 14.97          | 56.67 ± 15.49        | 0.3533a |
| Gender                           |                        |                      |         |                        |                      |         |
| Male, n (%)                      | 75 (57.69%)            | 13 (39.39%)          | 0.0596b | 75 (59.06%)            | 13 (36.11%)          | 0.0148b |
| Female, n (%)                    | 55 (42.31%)            | 20 (60.61%)          |         | 52 (40.94%)            | 23 (63.89%)          |         |
| Comorbidities                    |                        |                      |         |                        |                      |         |
| Diabetes, n (%)                  | 22 (16.92%)            | 5 (15.15%)           | 0.8069b | 22 (17.32%)            | 5 (13.89%)           | 0.6249b |
| Hypertension, n (%)              | 33 (25.38%)            | 15 (45.45%)          | 0.0239b | 33 (25.98%)            | 14 (38.89%)          | 0.1314b |
| Cardiac-cerebrovascular disease, n (%) | 20 (15.38%)        | 11 (33.33%)          | 0.0190b | 21 (16.54%)            | 10 (27.78%)          | 0.1292b |
| Respiratory diseases, n (%)      | 5 (3.85%)              | 3 (9.09%)            | 0.2130b | 4 (3.15%)              | 4 (11.11%)           | 0.0724b |
| Tumor, n (%)                     | 3 (2.31%)              | 2 (6.06%)            | 0.2665b | 3 (2.36%)              | 2 (5.56%)            | 0.3051b |
| Clinical classification           |                        |                      |         |                        |                      |         |
| Mild, n (%)                      | 2 (1.54%)              | 0 (0)                |         | 2 (1.57%)              | 0 (0)                |         |
| General, n (%)                   | 86 (66.15%)            | 18 (54.55%)          | 0.2153b | 82 (64.57%)            | 22 (61.11%)          | 0.7033b |
| Severe, n (%)                    | 23 (17.69%)            | 2 (6.06%)            | 0.1121b | 23 (18.11%)            | 2 (5.56%)            | 0.0650b |
| Critical, n (%)                  | 19 (14.62%)            | 13 (39.39%)          | 0.0014b | 20 (15.75%)            | 12 (33.33%)          | 0.0190b |
| Positive conversion time for SARS-CoV-2 RNA | 7.50 (4.00–13.00)    | 5.00 (3.00–7.50)     | 0.0022c | 8.00 (4.00–13.00)      | 5.00 (3.00–7.00)     | 0.0022c |
| Clinical laboratory test          |                        |                      |         |                        |                      |         |
| WBC, 10⁹/L                       | 5.59 (4.46–7.35)       | 4.86 (3.44–8.58)     | 0.4902c | 5.63 (4.53–7.42)       | 4.82 (3.40–8.32)     | 0.3250c |
| Neutrophil, 10⁹/L                | 3.47 (2.40–5.17)       | 3.47 (1.85–7.41)     | 0.8751c | 3.63 (2.44–5.24)       | 3.17 (1.93–7.08)     | 0.5982c |
| Lymphocyte, 10⁹/L                | 1.30 ± 0.61            | 0.90 ± 0.43          | 0.0005a | 1.29 ± 0.61            | 0.97 ± 0.49          | 0.0046a |
| Monocyte, 10⁹/L                  | 0.45 (0.33–0.64)       | 0.42 (0.31–0.56)     | 0.3646c | 0.44 (0.34–0.64)       | 0.42 (0.31–0.56)     | 0.4724c |
| RDW, (%)                         | 13.20 (12.68–13.70)    | 13.10 (12.55–13.95)  | 0.9975c | 13.20 (12.70–13.70)    | 13.05 (12.43–13.90)  | 0.7160c |
| Glucose, mmol/L                  | 5.48 (4.86–6.85)       | 5.98 (5.12–6.99)     | 0.2702c | 5.49 (4.86–7.02)       | 5.82 (5.09–6.77)     | 0.3930c |
| ALT, U/L                         | 27.00 (18.75–50.25)    | 24.00 (14.50–41.50)  | 0.2106c | 28.00 (20.00–50.25)    | 20.50 (14.00–39.50)  | 0.0274c |
| AST, U/L                         | 25.50 (19.00–30.00)    | 26.00 (19.50–51.00)  | 0.5849c | 26.00 (19.00–40.00)    | 25.50 (16.50–47.75)  | 0.5491c |
| BUN, mmol/L                      | 4.56 (3.71–5.66)       | 5.21 (3.49–8.36)     | 0.0119c | 4.55 (3.72–5.65)       | 5.15 (3.53–7.91)     | 0.1291c |
| CRP, mg/L                        | 8.45 (2.08–46.15)      | 15.23 (3.03–43.90)   | 0.5316c | 8.90 (2.00–48.70)      | 10.90 (2.95–44.15)   | 0.6416c |

Data was displayed as mean ± SD, median (IQR, interquartile range), or n (%).
* Two-tailed Student’s t test
χ² test
+ Non-parametric test (Mann–Whitney U test)

Positive conversion time for SARS-CoV-2 RNA defined as the first positive time point of RNA tests.

p < 0.05 was considered statistically significant (in bold).

Abbreviation: WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; RDW, red blood cell distribution width; N/A, not applicable.
positively associated with antibody positive results, while, the critical patients had a higher negative rate of IgM ($p = 0.002$) and IgG ($p = 0.022$). Additionally, cardiovascular and cerebrovascular diseases negatively associated with IgM positive results ($p = 0.022$), and the male ($p = 0.017$) and serum ALT level ($p = 0.002$) and IgG ($p = 0.032$) were the independent factors for antibody positive results after the adjustment for demographic and clinical characteristics. In addition, gender was also an independent factor that affecting IgG detection ($p = 0.032$).

**Discussion**

In the present study, we reviewed the positive conversion for RNA and antibody (IgM and IgG) in patients with COVID-19 and recommended the suitable time duration for positive test results. The median positive conversion time for RNA was the 7th day, while the median seroconversion time for IgM and IgG were both the 12nd days since onset of symptoms. Though the single detection for swabs RNA or antibodies was not enough for helping the diagnosis of COVID-19, combining detection assays at different times could maximize the positive rate. The results suggested that antibody tests could be an important supplement to RNA detection during the illness course, but some special patients with decreased lymphocytes could remain negative of antibody detection results. In this study, we analysed the consecutive throat swabs specimens from 187 COVID-19 patients. The median positive conversion time for SARS-CoV-2 RNA was day 7 (IQR, 3–11), which was consist with Chen et al. [10] reported day 6.5. The total positive rate was 40.65%, which was broadly in line with previously reported 38% [5]. However, the RT-qPCR showed a high positive rate (74.59%) in the early stage (day 1–5), and gradually decreased as the disease duration was prolonged (less than 20% at day > 45, Figure 1.

![Figure 4. Lymphocyte counts in different subtypes of COVID-19 patients. Independent-samples t test was used to compare the variables in different groups. * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$.](image_url)

**Table 3.** Univariate and multivariate binary logistic analysis of influencing factors of IgM / IgG result judgment.

| Variables                      | Univariate | Multivariate | Univariate | Multivariate |
|--------------------------------|------------|--------------|------------|--------------|
|                                | IgM positive/negative (n = 163) |              | IgG positive/negative (n = 163) |              |
|                                | OR (95%CI) | $p$          | OR (95%CI) | $p$          |
|--------------------------------|------------|--------------|------------|--------------|
| Age                            | 0.98 (0.96–1.01) | 0.215 | 1.00 (0.97–1.04) | 0.987 |
| Gender                         | 2.10 (1.96–4.58) | 0.063 | 2.61 (1.92–7.42) | 0.072 |
| Comorbidities                  |            |              |            |              |
| Diabetes                       | 1.14 (0.40–1.28) | 0.807 | 1.53 (0.37–6.30) | 0.554 |
| Hypertension                   | 0.46 (0.21–1.02) | 0.057 | 0.45 (0.14–1.42) | 0.174 |
| Cardia-cerebrovascular disease | 0.36 (0.15–0.87) | 0.022 | 0.65 (0.18–2.42) | 0.523 |
| Respiratory diseases           | 0.40 (0.91–1.77) | 0.227 | 0.32 (0.05–1.91) | 0.209 |
| Tumor                          | 0.37 (0.60–2.29) | 0.282 | 0.19 (0.02–2.04) | 0.172 |
| Clinical classification        |            |              |            |              |
| Mild                            | N/A        |              | N/A        |              |
| General                        | 0.61 (0.28–1.33) | 0.218 | 1.0 (Ref) |              |
| Severe                         | 0.30 (0.07–1.34) | 0.116 | 2.90 (0.49–17.09) | 0.239 |
| Critical                       | 0.26 (0.11–0.62) | 0.002 | 0.35 (0.07–1.73) | 0.197 |
| Positive conversion time for SARS-CoV-2 RNA | 1.11 (1.02–1.21) | 0.014 | 1.16 (1.03–1.31) | 0.014 |
| Clinical laboratory test        |            |              |            |              |
| WBC, 10$^9$/L                   | 1.01 (0.91–1.11) | 0.900 | 1.01 (0.92–1.12) | 0.793 |
| Neutrophil, 10$^3$/L            | 0.98 (0.89–1.07) | 0.644 | 0.99 (0.90–1.09) | 0.422 |
| Lymphocyte, 10$^3$/L            | 3.91 (1.73–8.821) | 0.001 | 3.48(1.25–9.71) | 0.017 |
| Monocyte, 10$^3$/L              | 1.68 (0.30–9.47) | 0.559 | 1.30 (0.25–6.69) | 0.755 |
| RDW, (%)                       | 0.82 (0.66–1.03) | 0.088 | 0.85 (0.68–1.06) | 0.157 |
| Glucose, mmol/L                | 0.96 (0.84–1.10) | 0.568 | 0.99 (0.86–1.13) | 0.843 |
| ALT, U/L                       | 1.02 (1.00–1.03) | 0.087 | 1.02 (0.99–1.04) | 0.220 |
| AST, U/L                       | 1.00 (0.99–1.01) | 0.929 | 1.01 (0.99–1.02) | 0.501 |
| BUN, mmol/L                    | 0.95 (0.90–1.01) | 0.122 | 0.98 (0.92–1.04) | 0.406 |
| CRP, mg/L                      | 1.00 (1.00–1.01) | 0.485 | 1.00 (1.00–1.01) | 0.375 |

Abbreviation: WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; RDW, red blood cell distribution width; IL-6, interleukin-6; N/A, not applicable; Ref, reference. $p < 0.05$ was considered statistically significant (in bold).
Supplementary Table S1). Notably, there were 27 patients (14.44%, 27/187) underwent multiple negative nucleic acid tests before confirmed diagnosis were made. This indicated that in addition to multiple tests for RNA with the same patient, other detection techniques are needed in the supplement to the current diagnostic shortages for RNA testing, especially at the late stage.

The results of IgM and IgG from serial serum samples suggested that 100% of the patients had antibody responses to SARS-CoV-2 during the course of disease. The median day of seroconversion for both IgG and IgM was 12 days since the symptom onset, which was to a certain extent in accordance with a previous publication. As Long et al. [11] found that the median day of seroconversion for both IgG and IgM was 13 days since symptom onset; while Zhao et al. [12] reported the median seroconversion day of IgM was 13 days since symptom onset; which was to a certain extent in accordance with a previous publication. As Long et al. [11] found that the median day of seroconversion for both IgG and IgM was day-12 and day-14, respectively. However, the reported median day of seroconversion was variable and ranged from 5 to 14 days [11–14], which required consideration of the sensitivity of the assay, the type of antigen, sample size and the duration of follow-up for the cohort [14]. Of note, there was one patient (No. 13, Figure S2) obtained the positive results of both IgM and IgG at day 36. The late seroconversion of antibody had also been reported in SARS-CoV. As Chen et al. [15] reported that the antibody of SARS-CoV might be positive as early as 8–10 days since the onset of illness and often by day 14, but sometimes a positive result was not achieved until 28 days since illness onset. In addition to the error caused by the lack of intermediate serum samples, impaired immune function might also contribute to the blunted responses against SARS-CoV-2 antigens [16].

Moreover, our results from 409 patients with COVID-19 showed that the positive rates of IgM and IgG were both low in early stage (Figure 1 and Supplementary Table S2), and gradually increased with the prolongation of disease courses, which consistent with the previous study [13,17]. However, the positive rate of RNA was the highest in the early stage and gradually decreased as the disease duration was prolonged. Moreover, there was a crossing for the RT-qPCR method and IgM/IgG testing at about 10 days, which was later than Guo, et al reported 5.5 days [13]. Anyway, the serological methods of IgM or IgG could be an important supplement to RNA detection, especially during the later illness course (such as > 10 days), and RNA detection can supplement the low sensitivity of antibody detection in the early stages of illness course. Combined RNA and antibody detection could potentially improve diagnostic efficiency. However, there were 53 patients confirmed by RT-qPCR had negative results of IgM or IgG. This may because the majority of these serum samples (73.58% for IgM, 84.91% for IgG) were collected at an earlier stage (≤ day 12), the specific immune response had not yet occurred or the antibody titres were too low to detect [9,13].

Multivariate logistic regression indicated that decreased lymphocyte counts were the independent factors leading to negative results of IgM and IgG antibody tests. As lymphocytes played an important role in producing antibodies, and reduced lymphocytes were common clinical features of COVID-19 patients, which suggested the impaired immune system of SARS-CoV-2 infected patients [18]. Moreover, decreased lymphocyte counts were associated with the disease severity, prognosis, and mortality of hospitalized COVID-19 patients [11,19–21]. Consistent with previous researches, we also found that as the severity of disease increased, lymphocytes showed a significant gradual decline in COVID-19 patients. Moreover, Shen et al. [22] and Kong et al. [23] reported that delayed antibody responses among severe COVID-19 patients. So we speculate that the decrease in lymphocytes of critically patients may lead to weak antibody responses or even negative antibody results in COVID-19 patients. Inconsistently, Zhao et al. [12] reported that a high antibody titre was a risk factor of critical illness, this might due to the antibodies used were different (we used antibodies against SARS-CoV-2 spike protein). As Sun et al. [24] reported that S-IgG against SARS-CoV-2 spike protein was significantly lower in ICU patients than in non-ICU patients, but the N-IgG against SARS-CoV-2 nucleocapsid protein showed the opposite result. Interestingly, the positive conversion time for SARS-CoV-2 RNA in antibody negative patients was significantly shorter than that in positive patients, and the short time for the positive detection might indicate the higher virus load [25,26]. Similarly, the levels of antibodies were inversely correlated with viral loads for MERS [27]. Furthermore, we found that gender was also an independent factor that affecting IgG detection, this may be due to the sex-specific immunobiological differences [28], but the exact mechanism was unclear. These data suggested that beside the course of disease, virus load as well as host immunology status could contribute toward the antibody response to the virus.

It should be noted that there were some limitations in this study. Firstly, this was a retrospective study which inherited all retrospective analyses limitation such as integrity of data, leading to incomplete overlap of the patients in different part. Secondly, qualitative RNA tests of patients were only based on upper respiratory tract specimens, lack of quantitative detection, and relatively low positive rate of SARS-CoV-2 RNA detection in throat swabs [25]. Thirdly, the sample size of serial serum analysis was small. Finally, the specificity analysis was inadequate in this study due to there was no real healthy controls.

In conclusion, this study indicated that the antibody response to SARS-CoV-2 could aid in the diagnosis of
COVID-19. The RNA testing displayed a high positive rate in the early stage, especially day 1–5, and the antibody methods showed a higher positive rate than that of RNA after 10 days since symptoms onset. We suggested to select different detection methods in different stages of the disease in order to improve the positive detection rate of patients with COVID-19. From the perspective of health economics, RNA detection in the early stage (1–5 day), combination of the RNA and antibody detection in the middle stage (6–45 day), and antibody detection in the advanced stage (> 45 day) could help to get the supporting result for the rapid diagnosis of COVID-19 (Table 4). And the understanding on the dynamic changes of RNA and antibody results, will help explaining the false negative results of RNA detection or antibody detection in the patients in different disease courses. Furthermore, this study was the first report about the influence factors of decreased lymphocytes and short positive conversion time on conversion of IgM and IgG against SARS-CoV-2.

Acknowledgments
We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Hubei Province. Contributors: X.Q. and F.Z. conceived and designed experiments. J.S., X.W., G.C., N.Y. and X.X. performed the experiments. S.L., S.L., G.Y., Y.T., J.F. and W.X. contributed to clinical samples collection. H.H. and Y.L. were responsible for the clinical management. X.Q., J.S., X.W., and G.C. collected the data. X.Q. and Y.X. analyzed the data. X.Q., Y.X. and F.Z. wrote the manuscript. All authors reviewed the manuscript.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by Hubei Province Health and Family Planning Scientific Research Project (Grant No. WJ2018H0013).

References
[1] WHO. Coronavirus disease (COVID-19) Situation Report-108 [7 May 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus -2019/situation-reports.
[2] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019 Mar;17 (3):181–192.
[3] National Health Commission of the People’s Republic of China. The Guidelines for Diagnosis and Treatment of Novel Coronavirus Pneumonia (7th version): National Health Commission of China; [7 May 2020]. Available from: http://www.nhc.gov.cn/zyyzj/s7653p/202003/46c9294a7dfe4e680dc7f5912eb1989.shtml.
[4] Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–389.
[5] Liu R, Han H, Liu F, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020 Jun;505:172–175.
[6] Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020 Jul;92 (7):903–908.
[7] Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Jun;58(7):1070–1076.
[8] Wolff R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465–469.
[9] Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003 Jul 31;349(3):508–509.
[10] Chen Y, Chen L, Deng Q, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020 Jul;92(7):833–840.
[11] Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845–848.
[12] Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28;ciaa344.
[13] Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020 Jul 28;71(5):778–785.
[14] Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2020 Jul 14;ciaa979.
[15] Chen S, Lu D, Zhang M, et al. Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum. Eur J Clin Microbiol Infect Dis. 2005 Aug;24(8):549–553.
[16] Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020 Jun 29;222(2):206–213.
[17] Liu W, Liu L, Kou G, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020 May;58(6):e00461–20.
[18] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061.
[19] Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with COVID-19. Clin Chim Acta. 2020 Jun;505:172–175.

Table 4. Recommendations for laboratory testing of COVID-19 at different disease course.

| General days since symptom onset | RNA | IgM | IgG |
|----------------------------------|-----|-----|-----|
| 1–5                              | ++  | –   | –   |
| 6–10                             | ++  | +   | +   |
| 11–45                            | +   | ++  | +   |
| > 45                             | –   | ++  | ++  |

++: strong recommendation.
+: general recommendation.
: not recommend.
coronavirus disease-19. J Med Virol. 2020 Mar 17;10.1002/jmv.25767.

[20] Wang K, Zuo P, Liu Y, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clin Infect Dis. 2020 May 3;ciaa538.

[21] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062.

[22] Shen L, Wang C, Zhao J, et al. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect. 2020 Dec;9(1):1096–1101.

[23] Kong WH, Zhao R, Zhou JB, et al. Serologic response to SARS-CoV-2 in COVID-19 patients with different severity. Virol Sin. 2020 Jul 23;1–6.

[24] Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):940–948.

[25] Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020 Mar 19;382(12):1177–1179.

[26] To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 May;20(5):565–574.

[27] Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients With Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2016 Feb 15;62(4):477–483.

[28] Gemmati D, Bramanti B, Serino ML, et al. COVID-19 and Individual Genetic Susceptibility/receptivity: role of ACE1/ACE2 genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in females Be Protective against SARS-CoV-2 compared to the single X-Chromosome in males? Int J Mol Sci. 2020 May 14;21(10):3474.